TABLE 5.

Likelihood ratio test of significance of HbA_1c, collagen variables, and collagen variables after adjusting for HbA_1c

	Intensive treatment									Conventional treatment
	HbA1c			Collagen variables			Collagen variables after adjusting for HbA1c			HbA1c			Collagen variables			Collagen variables after adjusting for HbA1c
	df	R2	P	df	R2	P	df	R2	P	df	R2	P	df	R2	P	df	R2	P
Retinopathy
Sustained ≤3-step progression	3	17	<0.011	6	28	<0.005	6	15	NS	3	13	<0.024	6	7	NS	6	5	NS
Sustained ≤3 microaneurysms	3	37	<0.001	6	26	<0.019	6	33	<0.005	3	14	<0.023	10	47	<0.001	10	43	<0.001
Rate of change of ETDRS	3	27	<0.001	7	19	<0.002	7	10	<0.030	3	24	<0.001	6	14	<0.040	6	7	NS
Nephropathy
AER >40 (mg/24 h)	2	55	<0.001	7	23	NS	7	6	NS	2	10	<0.037	7	40	<0.001	7	32	<0.006
Rate of change of AER	2	5	NS	7	10	NS	7	7	NS	2	4	NS	6	20	<0.005	6	16	<0.019
Neuropathy
Confirmed clinical neuropathy	3	7	NS	6	36	<0.004	6	37	<0.003	3	5	NS	6	51	<0.001	6	67	<0.001
Median NCV (m/s)	3	4	NS	8	16	<0.013	8	14	<0.034	3	18	<0.001	7	31	<0.001	7	18	<0.004

df = 6 corresponds to a model with six linear (collagen) effects. df > 6 corresponds to a model with six linear and (df – 6) quadratic effect(s). Sustained ≥3 microaneurysms includes the primary cohort only. Rate of change is (closeout – baseline)/length of follow-up. Confirmed clinical neuropathy is defined as an abnormal neurological examination that was consistent with the presence of peripheral sensorimotor neuropathy plus either abnormal nerve conduction in at least two peripheral nerves or unequivocally abnormal autonomic nerve setting (at 5 years). NCV, nerve conduction velocity.